Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease

N/AEnrolling By InvitationNCT06880250

NPO Petrovax100 enrolled

Overview

The goal of this observational study is to learn how enzyme replacement therapy works in patients with Fabry disease. The main question it aims to answer is: What medical problems do participants have? Participants already on enzyme replacement therapy as part of their regular medical care for Fabry disease will be observed as usual. Their data will be collected by their doctor.

All patients on enzyme replacement therapy could be enrolled in the study. Three medicines are currently available in Russia (Fabagal®, Fabrazyme®, Replagal®) so the patients form three cohorts. For all patients retrospective data are collected for 12 months prior enrollment. All patients are observed prospectively for 6 months. At the point of 6 months patients taking Fabrazyme or Replagal at the moment finish the study. Patients on Fabagal are observed for 12 more months (up to 18 months after enrollment).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Fabry Disease

Eligibility

Sex: ALLMin age: 8 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women with a confirmed diagnosis of Fabry disease; * Prescribed course of enzyme replacement therapy with any drug (Fabagal, Fabrazyme, Replagal); * Age 8 - 65 years; * Signed informed consent of the patient and/or patient's legal representative for participation in the study and processing of personal data. Exclusion Criteria: * Renal replacement therapy or kidney transplantation; * Critical illness unrelated to Fabry disease; * Pregnancy or breastfeeding; * Refusal of the patient (or patient's legal representative) from further participation in the study or medical care.

Locations (23)

#13

Astrakhan, Russia

#27

Barnaul, Russia

Borovichi, Russia

Outcomes

Primary Outcomes

Change from Baseline in Lyso-Gb3 Level

Level of globotriaosylsphingosine (lyso-Gb3) is measured in dried blood spots.

Time frame: From 12 months before enrollment up to 6 months (for Fabrazyme and Replagal cohorts) or up to 18 months (for Fabagal cohort) of observation

Secondary Outcomes

Change from Baseline in α-GAL Activity

Level of α-Galactosidase (α-GAL) activity is measured in dried blood spots.

Time frame: From 12 months before enrollment up to 6 months (for Fabrazyme and Replagal cohorts) or up to 18 months (for Fabagal cohort) of observation

Change from Baseline in GFR

Glomerular filtration rate (GFR) is measured by methods available in routine medical use.

Time frame: From 12 months before enrollment up to 6 months (for Fabrazyme and Replagal cohorts) or up to 18 months (for Fabagal cohort) of observation

Change from Baseline in Neuropathic Pain Level

Neuropathic pain is assessed according to verbal scale: no pain, mild pain, moderate pain, severe pain, very severe pain, intolerable pain. Corresponding value of 0, 2, 4, 6, 8, 10 is assigned.

Time frame: From enrollment up to 6 months (for Fabrazyme and Replagal cohorts) or up to 18 months (for Fabagal cohort) of observation

Incidence Rate of Significant Clinical Outcomes

Significant clinical outcomes include cardiac rhythm disturbances (atrial fibrillation, persistent supraventricular or ventricular tachycardia), heart failure, stroke, initiation of renal replacement therapy and death from any cause.

Time frame: From enrollment up to 6 months (for Fabrazyme and Replagal cohorts) or up to 18 months (for Fabagal cohort) of observation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.